The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hemophilia market reached a value of US$ XX Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hemophilia is a rare disorder wherein the blood clotting process is slowed due to the lack of sufficient blood-clotting proteins. Patients with this condition experience prolonged bleeding or oozing after an injury, surgery, or a tooth is pulled. In severe cases, continuous bleeding may also occur after minor trauma or even in the absence of injury. On the other hand, its milder form does not involve spontaneous bleeding. As a result, the condition may not become apparent until abnormal bleeding occurs.
The rising number of hemophilic patients around the world represents one of the key factors propelling the growth of the market. Additionally, the increasing diagnosis rate and the growing use of prophylactic treatment for hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, due to the availability of limited treatment therapy, governing agencies of numerous countries are funding research and development (R&D) activities to identify therapeutic agents. They are also launching numerous campaigns to generate awareness about early diagnosis and undertaking initiatives to commence early screening of neonates. This is positively influencing the need for diagnostic tools of hemophilia worldwide. Besides this, the rising number of organizations like the World Federation of Hemophilia (WFH) and the National Hemophilia Foundation (NHF) is also impelling the market growth. These organizations help find treatments for inheritable bleeding disorders and prevent complications of these disorders through education, research, and advocacy. Furthermore, several companies are adopting strategies for increasing their sales and geographic expansion, especially in the Middle Eastern and West African countries. For instance, BioMarin Pharmaceutical Inc. is focusing on the development of Valoctocogene Roxaparvovec (BMN-270) for treating type A patients.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on type, treatment and therapy.
Breakup by Type:
Breakup by Treatment:
Breakup by Therapy:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Treatment, Therapy, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at